The effect of ritonavir on human CYP2B6 catalytic activity: Heme modification contributes to the mechanism-based inactivation of CYP2B6 and CYP3A4 by ritonavir

Drug Metabolism and Disposition

Volumn 41, Issue 10, 2013, Pages 1813-1824

  Lin, Hsia Lien ^a   D'Agostino, Jaime ^a   Kenaan, Cesar ^a   Calinski, Diane ^a   Hollenberg, Paul F ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPROTEIN; CYTOCHROME P450 2B6; CYTOCHROME P450 3A4; HEMOPROTEIN; RITONAVIR;

ARTICLE; CATALYSIS; CONTROLLED STUDY; CRYSTAL STRUCTURE; DEACETYLATION; DRUG ACTIVITY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME KINETICS; ENZYME RECONSTITUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; TANDEM MASS SPECTROMETRY;

APOPROTEINS; ARYL HYDROCARBON HYDROXYLASES; CATALYSIS; CYTOCHROME P-450 CYP3A; GLUTATHIONE; HEME; HUMANS; MICROSOMES, LIVER; RITONAVIR;

EID: 84884693033     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.053108     Document Type: Article

References (51)

1. Avants SK, Margolin A, DePhilippis D, and Kosten TR (1998) A comprehensive pharmacologic-psychosocial treatment program for HIV-seropositive cocaine- and opioid-dependent patients. Preliminary findings. J Subst Abuse Treat 15:261-265. (Pubitemid 28302847)
2. Baillie TA and Davis MR (1993) Mass spectrometry in the analysis of glutathione conjugates. Biol Mass Spectrom 22:319-325. (Pubitemid 23165443)
3. Bruno R, Sacchi P, Maiocchi L, Patruno S, and Filice G (2006) Hepatotoxicity and antiretroviral therapy with protease inhibitors: A review. Dig Liver Dis 38:363-373. (Pubitemid 44356213)
4. Chen H, Zientek M, Jalaie M, Zhang Y, Bigge C, and Mutlib A (2009) Characterization of cytochrome P450-mediated bioactivation of a compound containing the chemical scaffold, 4,5- dihydropyrazole-1-carboxylic acid-(4-chlorophenyl amide), to a chemically reactive p-chlorophenyl isocyanate intermediate in human liver microsomes. Chem Res Toxicol 22:1603-1612.
5. Daali Y, Ancrenaz V, Bosilkovska M, Dayer P, and Desmeules J (2011) Ritonavir inhibits the two main prasugrel bioactivation pathways in vitro: a potential drug-drug interaction in HIV patients. Metabolism 60:1584-1589.
6. Duggan ST and Keating GM (2009) Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Drugs 69:1707-1726.
7. Ernest CS, 2nd, Hall SD, and Jones DR (2005) Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther 312:583-591. (Pubitemid 40189555)
8. Ferrando SJ, Goldman JD, and Charness WE (1997) Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS. Improvements in affective and somatic symptoms. Gen Hosp Psychiatry 19:89-97. (Pubitemid 27146816)
9. Floridia M, Bucciardini R, Fragola V, Galluzzo CM, Giannini G, Pirillo MF, Amici R, Andreotti M, Ricciardulli D, and Tomino C, et al.; ISS-IP1 study group (2004) Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleosideexperienced patients with very low CD4 levels (<50 cells/microL). HIV Med 5:1-10. (Pubitemid 38219974)
10. Foisy MM, Yakiwchuk EM, and Hughes CA (2008) Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 42:1048-1059.
11. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V, Martin H, Beaune P, and de Waziers I (1999) Human CYP2B6: expression, inducibility and catalytic activities. Pharmacogenetics 9:295-306. (Pubitemid 29376373)
12. Goosen TC, Mills DE, and Hollenberg PF (2001) Effects of benzyl isothiocyanate on rat and human cytochromes P450: identification of metabolites formed by P450 2B1. J Pharmacol Exp Ther 296:198-206. (Pubitemid 32015079)
13. Goossens A, Detienne T, and Bruze M (2002) Occupational allergic contact dermatitis caused by isocyanates. Contact Dermat 47:304-308. (Pubitemid 36174242)
14. Granfors MT, Wang JS, Kajosaari LI, Laitila J, Neuvonen PJ, and Backman JT (2006) Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin Pharmacol Toxicol 98:79-85.
15. Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS, and Shader RI (1999) Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J Clin Psychopharmacol 19:293-296. (Pubitemid 29344840)
16. Hesse LM, von Moltke LL, Shader RI, and Greenblatt DJ (2001) Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 29:100-102. (Pubitemid 32112922)
17. Hull MW and Montaner JS (2011) Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med 43:375-388.
18. Jochheim CM, Davis MR, Baillie KM, Ehlhardt WJ, and Baillie TA (2002) Glutathionedependent metabolism of the antitumor agent sulofenur. Evidence for the formation of pchlorophenyl isocyanate as a reactive intermediate. Chem Res Toxicol 15:240-248. (Pubitemid 34163805)
19. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, and Baroldi PA, et al. (1997) Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 41:654-660. (Pubitemid 27098420)
20. Kent UM, Lin HL, Mills DE, Regal KA, and Hollenberg PF (2006) Identification of 17-alpha-ethynylestradiol- modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6. Chem Res Toxicol 19:279-287.
21. Kharasch ED, Mitchell D, Coles R, and Blanco R (2008) Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother 52:1663-1669. (Pubitemid 351614658)
22. Kirby BJ, Collier AC, Kharasch ED, Dixit V, Desai P, Whittington D, Thummel KE, and Unadkat JD (2011a) Complex drug interactions of HIV protease inhibitors 2: in vivo induction and in vitro to in vivo correlation of induction of cytochrome P450 1A2, 2B6, and 9 by ritonavir or nelfinavir. Drug Metab Dispos 39:2329-2337.
23. Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, and Unadkat JD (2011b) Complex drug interactions of HIV protease inhibitors 1: inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos 39:1070-1078.
24. Korhonen LE, Turpeinen M, Rahnasto M, Wittekindt C, Poso A, Pelkonen O, Raunio H, and Juvonen RO (2007) New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis. Br J Pharmacol 150:932-942. (Pubitemid 46536632)
25. Koudriakova T, Iatsimirskaia E, Utkin I, Gangl E, Vouros P, Storozhuk E, Orza D, Marinina J, and Gerber N (1998) Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. Drug Metab Dispos 26:552-561.
26. Kumar GN, Rodrigues AD, Buko AM, and Denissen JF (1996) Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 277:423-431. (Pubitemid 27169089)
27. Lang T, Klein K, Fischer J, Nüssler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415. (Pubitemid 32656581)
28. Li F, Lu J, and Ma X (2011) Metabolomic screening and identification of the bioactivation pathways of ritonavir. Chem Res Toxicol 24:2109-2114.
29. Lin HL and Hollenberg PF (2007) The inactivation of cytochrome P450 3A5 by 17alphaethynylestradiol is cytochrome b5-dependent: metabolic activation of the ethynyl moiety leads to the formation of glutathione conjugates, a heme adduct, and covalent binding to the apoprotein. J Pharmacol Exp Ther 321:276-287.
30. Lin HL, Kenaan C, and Hollenberg PF (2012) Identification of the residue in human CYP3A4 that is covalently modified by bergamottin and the reactive intermediate that contributes to the grapefruit juice effect. Drug Metab Dispos 40:998-1006.
31. Lin HL, Kent UM, and Hollenberg PF (2002) Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein. J Pharmacol Exp Ther 301:160-167.
32. Lin HL, Zhang H, and Hollenberg PF (2009) Metabolic activation of mifepristone [RU486; 17beta-hydroxy-11beta-(4-dimethylaminophenyl)-17alpha-(1- propynyl)-estra-4,9-dien-3-one] by mammalian cytochromes P450 and the mechanism-based inactivation of human CYP2B6. J Pharmacol Exp Ther 329:26 -37.
33. Lin HL, Zhang H, Pratt-Hyatt MJ, and Hollenberg PF (2011) Thr302 is the site for the covalent modification of human cytochrome P450 2B6 leading to mechanism-based inactivation by tertbutylphenylacetylene. Drug Metab Dispos 39:2431-2439.
34. Liu Q and Wisnewski AV (2003) Recent developments in diisocyanate asthma. Ann Allergy Asthma Immunol 90 (Suppl 2):35-41. (Pubitemid 36828136)
35. Moreno RL, Goosen T, Kent UM, Chung FL, and Hollenberg PF (2001) Differential effects of naturally occurring isothiocyanates on the activities of cytochrome P450 2E1 and the mutant P450 2E1 T303A. Arch Biochem Biophys 391:99-110. (Pubitemid 32612577)
36. Osawa Y and Pohl LR (1989) Covalent bonding of the prosthetic heme to protein: a potential mechanism for the suicide inactivation or activation of hemoproteins. Chem Res Toxicol 2: 131-141. (Pubitemid 19159939)
37. Palella FJ, Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, and Holmberg SD and the HIV Outpatient Study Investigators (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338:853-860. (Pubitemid 28135961)
38. Piscitelli SC, Flexner C, Minor JR, Polis MA, and Masur H (1996) Drug interactions in patients infected with human immunodeficiency virus. Clin Infect Dis 23:685-693. (Pubitemid 26331107)
39. Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, D'Arminio Monforte A, and Friis-Møller N, et al.; D:A:D Study Group (2008) Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration. Lancet 371:1417-1426.
40. Scott EE, Spatzenegger M, and Halpert JR (2001) A truncation of 2B subfamily cytochromes P450 yields increased expression levels, increased solubility, and decreased aggregation while retaining function. Arch Biochem Biophys 395:57-68. (Pubitemid 33030143)
41. Sevrioukova IF and Poulos TL (2010) Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc Natl Acad Sci USA 107:18422-18427.
42. Sevrioukova IF and Poulos TL (2012) Interaction of human cytochrome P4503A4 with ritonavir analogs. Arch Biochem Biophys 520:108-116.
43. Silverman R (1996) Mechanism-based enzyme inactivation, in Contemporary Enzyme Kinetics and Mechanisms (Purich DL ed) pp 291-335, Academic Press, San Diego, CA.
44. Talakad JC, Kumar S, and Halpert JR (2009) Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs. Drug Metab Dispos 37: 644-650.
45. Turpeinen M, Raunio H, and Pelkonen O (2006) The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors in vitro, in vivo and in silico. Curr Drug Metab 7:705-714. (Pubitemid 44509677)
46. von Moltke LL, Durol AL, Duan SX, and Greenblatt DJ (2000) Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur J Clin Pharmacol 56:259-261. (Pubitemid 30456687)
47. von Moltke LL, Greenblatt DJ, Grassi JM, Granda BW, Duan SX, Fogelman SM, Daily JP, Harmatz JS, and Shader RI (1998) Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 38:106-111. (Pubitemid 28117365)
48. Wang H and Tompkins LM (2008) CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9:598-610.
49. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, and Schwab M (2007) Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8:743-759. (Pubitemid 47288975)
50. Zeldin RK and Petruschke RA (2004) Pharmacological and therapeutic properties of ritonavirboosted protease inhibitor therapy in HIV-infected patients. J Antimicrob Chemother 53: 4-9. (Pubitemid 38072176)
51. Zhang H, Lin HL, Walker VJ, Hamdane D, and Hollenberg PF (2009) tert-Butylphenylacetylene is a potent mechanism-based inactivator of cytochrome P450 2B4: inhibition of cytochrome P450 catalysis by steric hindrance. Mol Pharmacol 76:1011-1018.